[1] |
MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu.
Correlation between 25(OH)D and metabolically related fatty liver in T2DM population
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
|
[2] |
MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai.
Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
|
[3] |
LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao.
Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
|
[4] |
HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun.
Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
|
[5] |
HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu.
Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
|
[6] |
ZHAO Shifeng, SONG Xiangming, YAO Jianping.
Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
|
[7] |
DU Xiaoyu, LI Yumeng, WU Huizhen, QIU Bo.
Pharmacological and clinical evaluation of Dorzagliatin in the treatment of type 2 diabetes
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1177-1183.
|
[8] |
CAI Jing, PAN Binjing, LIU Jingfang.
Research progress on the relationship between hypoglycemic drugs and sarcopenia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 101-108.
|
[9] |
ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen.
Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
|
[10] |
LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei.
Research progress of virus-mediated gene therapy in type 2 diabetes mellitu
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
|
[11] |
ZENG Xiaofan, XU Yiqi, LIU Shu, WU Qian, LI Zibao, HE Junjun, JIN Yuelong, ZHAO Yongli, HE Chunling, GAO Jialin.
Retrospectively analysis of the effect of low-dose aspirin on primary prevention of non-fatal myocardial infarction and cerebral infarction in patients with type 2 diabetes mellitus
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 665-671.
|
[12] |
LIU Yizhen, REN Lingxuan, YANG Jianjun, HE Jianyu, LIU Xiaojun, WANG Long, LIN Rong.
Study on the screening of active constituents of Taohong Siwu Decoction and the protective effect of ferulic acid on myocardial injury
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 505-515.
|
[13] |
LI Hao, LI Ling, XIA Zhiping, YE Qifa, PENG Guizhu.
FXR agonist GW4064 ameliorates tacrolimus-induced abnormalities in glucose metabolism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 466-472.
|
[14] |
SHAO Xi, YU Yanan, HUANG Yuhan, WANG Xiaotong, LING Hongwei, LV Dongmei, WANG Tao.
Predictive factors associated with weight response to exenatide in patients with type 2 diabetes mellitus
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 287-294.
|
[15] |
LV Xiaohan, LIN Rong.
Association of Lin28 with tumor, cardiovascular disease and diabetes
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 205-211.
|